Health
Novo Nordisk Launches Wegovy™ Pill, Expanding Patient Choice and Access With knownwell as a Recognized NovoCare® Provider
BOSTON, January 05, 2026--Novo Nordisk today announced the U.S. launch of the Wegovy™ pill, the first oral GLP-1 option approved by the Food and Drug Administration for chronic weight management. The introduction of an oral formulation marks a significant step forward in expanding patient choice, and access to evidence-based obesity treatment.
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/e0c73088508f184868b56666f43550f9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eaDjT1x72gNPbarRbj7tXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e0c73088508f184868b56666f43550f9","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NjeyGDgpbA8EzC8f4ujCeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/e0c73088508f184868b56666f43550f9","width":1024,"height":512}},"lazy":false},{"type":"text","content":"As the first and only FDA-approved oral GLP-1 launches, NovoCare® expands its offerings to help patients find access to comprehensive, clinician-led metabolic care nationwide.","length":175,"tagName":"p"},{"type":"text","content":"BOSTON, January 05, 2026--(BUSINESS WIRE)--Novo Nordisk today announced the U.S. launch of the Wegovy™ pill, the first oral GLP-1 option approved by the Food and Drug Administration for chronic weight management. The introduction of an oral formulation marks a significant step forward in expanding patient choice, and access to evidence-based obesity treatment.","length":362,"tagName":"p"},{"type":"text","content":"The launch coincides with an expanded NovoCare® experience, designed to help patients find trusted care, understand coverage options, and access ongoing support throughout their treatment journey. As part of this experience, patients seeking treatment with real FDA-approved products, now including the Wegovy™ pill, can connect with recognized care providers that offer comprehensive, longitudinal obesity care.","length":412,"tagName":"p"},{"type":"text","content":"knownwell, a weight-inclusive primary care and metabolic health company offering both virtual and in-person care, is proud to be recognized as a NovoCare® provider. Through this engagement, patients exploring the Wegovy™ pill can be connected to knownwell’s multidisciplinary care model, which integrates medical, nutritional, and behavioral support delivered through a national hybrid model.","length":392,"tagName":"p"},{"type":"text","content":""The availability of Wegovy pill represents an important...